Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 9/20 | 0.35 |
| ▸ | MMP13 | P45452 | 2/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4038647 | 0.88 | LMNA (0.39) | ACHEMCHR1OPRL1GAAKMT2A | |
| SCHEMBL3994486 | 0.85 | MCHR1 (0.37) | ACHEMCHR1MMP13SIGMAR1GAA | |
| SCHEMBL1810683 | 0.85 | ACHE (0.36) | ACHEMCHR1MMP13OPRL1SIGMAR1 | |
| SCHEMBL3995879 | 0.84 | KMT2A (0.38) | ACHEMCHR1MMP13OPRL1SIGMAR1 | |
| SCHEMBL4033395 | 0.83 | MCHR1 (0.36) | ACHEMCHR1MMP13SIGMAR1GAA | |
| SCHEMBL1809029 | 0.83 | TSHR (0.43) | MCHR1GAAKMT2A | |
| SCHEMBL4046162 | 0.83 | MCHR1 (0.38) | ACHEMCHR1SIGMAR1GAAKMT2A | |
| SCHEMBL4035185 | 0.82 | SMN1; SMN2 (0.40) | KMT2A | |
| SCHEMBL4206788 | 0.81 | KMT2A (0.35) | ACHEMCHR1MMP13OPRL1SIGMAR1 | |
| SCHEMBL1808149 | 0.80 | DRD4 (0.39) | MCHR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7560468-B2 | Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2009-07-14 | — | — | US | claimed |
| US-20070015783-A1 | Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2007-01-18 | — | — | US | claimed |
| US-7560468-B2 | Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2009-07-14 | — | — | US | disclosed |
| US-20070015783-A1 | Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015783-A1 | Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds | THPO, UGT1A8, UGT1A4 | ACHE 3431/4885MCHR1 1399/4885MMP13 3451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.